A Two Part, Multiple Dose Clinical Trial of the Safety and Efficacy of ABX-EGF [panitumumab] in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer

Trial Profile

A Two Part, Multiple Dose Clinical Trial of the Safety and Efficacy of ABX-EGF [panitumumab] in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2013

At a glance

  • Drugs Panitumumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 02 Oct 2005 New trial record.
    • 31 Mar 2003 Recruitment completed, according to results published in the Thoracic Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top